Loading...
Loading...
ANVS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 10.0M |
| Operating I/L | 10.0M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.2M |
| Pretax | -9.7M |
| Income Tax Expense | 19.7M |
| Net Income/Loss | -29.4M |
Annovis Bio, Inc. is a clinical stage drug platform company focused on developing drugs to treat neurodegenerative diseases. Its lead compound, Buntanetap, has completed Phase 2a clinical trials for Alzheimer's disease and Parkinson's disease, and is also being tested for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. The company is also developing ANVS405 for traumatic brain injury and stroke protection, and ANVS301, currently in Phase I clinical trials, to enhance cognitive capability in later stages of Alzheimer's disease and dementia.
